DGKB and neoplasm: Although we cannot rule out the possibility that these compounds are simply not effective in Drosophila, these results overall indicate that the key target for ritanserin is Dgk, rather than serotonin receptors, in its synergistic effect with trametinib in reducing Ras-driven polarity-impaired tumour growth.